Literature DB >> 11034115

Potential involvement of mt1 receptor and attenuated sex steroid-induced calcium influx in the direct anti-proliferative action of melatonin on androgen-responsive LNCaP human prostate cancer cells.

S C Xi1, P C Tam, G M Brown, S F Pang, S Y Shiu.   

Abstract

Melatonin, a pineal secretory product, has been shown to exert a direct anti-proliferative action on the androgen-sensitive LNCaP prostate cancer cell line through hitherto undefined mechanisms. In this communication, expression of mt1 melatonin receptor protein in human prostate cancer tissues and LNCaP cells was demonstrated by immunohisto(cyto)chemistry and western blotting, hence supporting the use of LNCaP cell line as a model for the study of melatonin signaling in prostate cancer cell growth. Using 3H-thymidine incorporation assay, LNCaP cell proliferation was inhibited by 2-iodomelatonin, a high-affinity melatonin receptor agonist. Furthermore, melatonin inhibited 3H-thymidine incorporation into LNCaP cells and attenuated 5alpha-dihydrotestosterone (DHT) or 17beta-estradiol (E2)-induced stimulation of LNCaP cell proliferation at physiological and pharmacological concentrations. Similar concentration-dependent inhibition of sex steroid-induced stimulation of thymidine incorporation into LNCaP cells by 2-iodomelatonin was also observed. Interestingly, attenuation of sex steroid-stimulated calcium influx into LNCaP cells by pharmacological concentrations of melatonin was recorded, whereas 2-iodomelatonin had no effect on cytosolic calcium changes induced by sex steroids. In addition, proliferative and cytosolic calcium changes were associated with inhibition of total prostate-specific antigen (PSA) production by LNCaP cells at high physiological and pharmacological concentrations of melatonin. Our data suggest that activated mt1 receptor and attenuated sex steroid-induced calcium influx are two important mechanisms mediating the direct anti-proliferative action of melatonin on androgen-responsive human prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11034115     DOI: 10.1034/j.1600-079x.2000.d01-64.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  12 in total

Review 1.  Circadian disruption, sleep loss, and prostate cancer risk: a systematic review of epidemiologic studies.

Authors:  Lara G Sigurdardottir; Unnur A Valdimarsdottir; Katja Fall; Jennifer R Rider; Steven W Lockley; Eva Schernhammer; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-05-07       Impact factor: 4.254

Review 2.  Expression and putative functions of melatonin receptors in malignant cells and tissues.

Authors:  Cem Ekmekcioglu
Journal:  Wien Med Wochenschr       Date:  2014-07-15

Review 3.  MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.

Authors:  Jiabei Liu; Shannon J Clough; Anthony J Hutchinson; Ekue B Adamah-Biassi; Marina Popovska-Gorevski; Margarita L Dubocovich
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-23       Impact factor: 13.820

4.  Melatonin Induces Apoptotic Cell Death via p53 in LNCaP Cells.

Authors:  Chi Hyun Kim; Yeong-Min Yoo
Journal:  Korean J Physiol Pharmacol       Date:  2010-12-31       Impact factor: 2.016

Review 5.  WOMEN IN CANCER THEMATIC REVIEW: Circadian rhythmicity and the influence of 'clock' genes on prostate cancer.

Authors:  Zsofia Kiss; Paramita M Ghosh
Journal:  Endocr Relat Cancer       Date:  2016-09-22       Impact factor: 5.678

6.  Night shift work and levels of 6-sulfatoxymelatonin and cortisol in men.

Authors:  Dana K Mirick; Parveen Bhatti; Chu Chen; Frank Nordt; Frank Z Stanczyk; Scott Davis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04-05       Impact factor: 4.254

Review 7.  Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis.

Authors:  Russel J Reiter; Sergio A Rosales-Corral; Dun-Xian Tan; Dario Acuna-Castroviejo; Lilan Qin; Shun-Fa Yang; Kexin Xu
Journal:  Int J Mol Sci       Date:  2017-04-17       Impact factor: 5.923

8.  Melatonin Analogue Antiproliferative and Cytotoxic Effects on Human Prostate Cancer Cells.

Authors:  Angela Calastretti; Giuliana Gatti; Valeria Lucini; Silvana Dugnani; Gianfranco Canti; Francesco Scaglione; Annamaria Bevilacqua
Journal:  Int J Mol Sci       Date:  2018-05-18       Impact factor: 5.923

9.  Association of melatonin membrane receptor 1A/1B gene polymorphisms with the occurrence and metastasis of hepatocellular carcinoma.

Authors:  Shih-Chi Su; Yung-Chuan Ho; Yu-Fan Liu; Russel J Reiter; Chia-Hsuan Chou; Chia-Ming Yeh; Hsiang-Lin Lee; Wen-Hung Chung; Ming-Ju Hsieh; Shun-Fa Yang
Journal:  Oncotarget       Date:  2017-09-20

10.  Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy.

Authors:  Vincent Wing Sun Liu; Wing Lung Yau; Chun Wai Tam; Kwok-Ming Yao; Stephen Yuen Wing Shiu
Journal:  Int J Mol Sci       Date:  2017-05-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.